Home > Press > Harris & Harris Group Invests in Nanoopto Corporation
Abstract:
$842,503 as part of a $12 million Series C
Harris & Harris Group, Inc., announced today that it
invested $842,503 as part of a $12 million Series C round of
financing by privately held NanoOpto Corporation
(www.nanoopto.com). First Analysis led the Series C financing and
existing equity partners Morgenthaler Ventures; U.S. Trust's
Excelsior Venture Partners III, L.L.C.; Draper Fisher Jurvetson
(DFJ) Gotham Ventures and New England Ventures; and Harris & Harris
Group all participated. Doug Jamison will represent Harris & Harris
Group on the board of NanoOpto. Harris & Harris Group originally
invested in NanoOpto in March 2002 and currently owns approximately
7.97 percent of the fully diluted equity in privately held NanoOpto.
NanoOpto is applying proprietary nano-fabrication technology
to the rapid design and high-volume manufacture of nano-optic
devices for optical components and systems. The company's nanometer
scale optical function design capability, combined with water-based
manufacturing methods, delivers optical components that are directed
at increasing performance and lowering cost.
Harris & Harris Group is a publicly traded venture capital
company that now makes initial investments exclusively in tiny
technology, including nanotechnology, microsystems and
microelectromechanical systems (MEMS). The Company's last 22 initial
private equity investments have been in tiny-technology enabled
companies.
Harris & Harris Group is a business development company with
17,248,845 common shares outstanding.
Detailed information about Harris & Harris Group and its
holdings can be found on its website at www.TinyTechVC.com.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||